tiprankstipranks
Advertisement
Advertisement

RGNX Stock Latest News

RegenXBio Raises Capital Through Public Equity Offering
Company AnnouncementsRegenXBio Raises Capital Through Public Equity Offering
12d ago
8K
RGNX
Regenxbio presents long-term data for surabgene lomparvovec
PremiumThe Fly
Regenxbio presents long-term data for surabgene lomparvovec
13d ago
RGNX
Midday Fly By: Netflix forecast fuels fears, SpaceX tumbles after scrubbing test
PremiumThe Fly
Midday Fly By: Netflix forecast fuels fears, SpaceX tumbles after scrubbing test
15d ago
AA
BP
Regenxbio 10M share Spot Secondary priced at $9.00
PremiumThe Fly
Regenxbio 10M share Spot Secondary priced at $9.00
15d ago
RGNX
Regenxbio announces $100M common stock offering
PremiumThe Fly
Regenxbio announces $100M common stock offering
16d ago
RGNX
RegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target
PremiumRatingsRegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target
1M ago
RGNX
Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial
Premium
Company Announcements
Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial
1M ago
8K
RGNX
Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial
Premium
The Fly
Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial
1M ago
ABBV
RGNX
RegenXBio: Advancing Late-Stage RGX-202 and Navsunli Programs Underpin Buy Rating, $16 Price Target Maintained
PremiumRatings
RegenXBio: Advancing Late-Stage RGX-202 and Navsunli Programs Underpin Buy Rating, $16 Price Target Maintained
1M ago
RGNX
Regenxbio completes dosing in confirmatory study of RGX-202
PremiumThe Fly
Regenxbio completes dosing in confirmatory study of RGX-202
1M ago
RGNX
Regenxbio price target raised to $32 from $27 at Baird
PremiumThe Fly
Regenxbio price target raised to $32 from $27 at Baird
1M ago
RGNX
H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission
PremiumThe Fly
H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission
1M ago
RGNX
Morning Movers: Getty Images skyrockets after OpenAI deal
PremiumThe FlyMorning Movers: Getty Images skyrockets after OpenAI deal
1M ago
ACA
APGE
Video: SpaceX dips after notes offering, KeyBanc initiation
Premium
The Fly
Video: SpaceX dips after notes offering, KeyBanc initiation
1M ago
ACA
CRH
Regenxbio aligns with FDA on path forward for Navsunli
Premium
The Fly
Regenxbio aligns with FDA on path forward for Navsunli
1M ago
RGNX
Regenxbio up 25% after saying FDA will reverse rejection, consider application
PremiumThe Fly
Regenxbio up 25% after saying FDA will reverse rejection, consider application
1M ago
RGNX
Regenxbio tells WSJ that FDA will reverse rejection of drug
PremiumThe Fly
Regenxbio tells WSJ that FDA will reverse rejection of drug
1M ago
QURE
REPL
Regenxbio price target lowered to $26 from $30 at H.C. Wainwright
PremiumThe Fly
Regenxbio price target lowered to $26 from $30 at H.C. Wainwright
2M ago
RGNX
Acting FDA head vows to block political interference, Endpoint News says
PremiumThe Fly
Acting FDA head vows to block political interference, Endpoint News says
2M ago
AZN
BMY
RegenXBio Launches Targeted Employee Stock Option Exchange
PremiumCompany AnnouncementsRegenXBio Launches Targeted Employee Stock Option Exchange
2M ago
8K
RGNX
FDA issues draft guidance to help accelerated cell, gene therapies for patients
Premium
The Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
2M ago
AZN
BMY
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook
Premium
Company Announcements
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook
2M ago
RGNX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >